Five Late-Breaking Studies To Look Out For At ASCO

 
• By Alexandra Shimmings

Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.    

More from Clinical Trials

More from R&D